- Home
- VYGR vs FXNC Comparison
VYGR vs FXNC Comparison
Compare VYGR & FXNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- FXNC
- Stock Information
- Founded
- VYGR 2013
- FXNC 1907
- Country
- VYGR United States
- FXNC United States
- Employees
- VYGR N/A
- FXNC N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- FXNC Major Banks
- Sector
- VYGR Health Care
- FXNC Finance
- Exchange
- VYGR Nasdaq
- FXNC Nasdaq
- Market Cap
- VYGR 222.9M
- FXNC 201.9M
- IPO Year
- VYGR 2015
- FXNC N/A
- Fundamental
- Price
- VYGR $3.16
- FXNC $18.60
- Analyst Decision
- VYGR Strong Buy
- FXNC Strong Buy
- Analyst Count
- VYGR 9
- FXNC 1
- Target Price
- VYGR $14.86
- FXNC $21.00
- AVG Volume (30 Days)
- VYGR 396.9K
- FXNC 22.1K
- Earning Date
- VYGR 05-12-2025
- FXNC 04-29-2025
- Dividend Yield
- VYGR N/A
- FXNC 3.32%
- EPS Growth
- VYGR N/A
- FXNC N/A
- EPS
- VYGR N/A
- FXNC 1.00
- Revenue
- VYGR $80,001,000.00
- FXNC $58,014,000.00
- Revenue This Year
- VYGR N/A
- FXNC $57.36
- Revenue Next Year
- VYGR $2.04
- FXNC $4.25
- P/E Ratio
- VYGR N/A
- FXNC $18.60
- Revenue Growth
- VYGR N/A
- FXNC 18.28
- 52 Week Low
- VYGR $2.75
- FXNC $14.50
- 52 Week High
- VYGR $9.55
- FXNC $26.97
- Technical
- Relative Strength Index (RSI)
- VYGR 38.34
- FXNC 24.00
- Support Level
- VYGR $2.75
- FXNC $18.50
- Resistance Level
- VYGR $3.34
- FXNC $21.00
- Average True Range (ATR)
- VYGR 0.26
- FXNC 0.85
- MACD
- VYGR 0.03
- FXNC -0.16
- Stochastic Oscillator
- VYGR 41.41
- FXNC 2.38
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About FXNC First National Corporation
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. Loan products and services include personal loans, residential mortgages, home equity loans, and commercial loans. Deposit products and services include checking and savings. The Bank's wealth management division offers estate planning, investment management of assets, retirement accounts, and estate settlement.